Acute myelogenous leukemia (AML) is a hematological malignancy, which accounts for about 15-25% of childhood's leukemia. Genetic factor is one of the most important predisposing elements in childhood acute leukemia, especially AML. In this case report, a rare presentation of familial AML is presented in three monozygotic triplets. Two were 10 months old, and the other one was 16 months old at p...

Acute myelogenous leukemia (AML) accounts for 1.2% of all cancer deaths. Relapse is the major cause of treatment failure in acute myeloid leukemia (AML) patients. AML rarely presents as ocular manifestation in relapse or at presentation. The M4 subtype of AML is most commonly presented with extramedullary involvement. In this report, we presented a young female with AML who was diagnosed and tr...

Evaluation of ATG7 and LC3 Autophagy Genes Expression in Newly Diagnosed AML patients Background and aim: Autophagy, known as cell death type II, is a housekeeping pathway that currently has been worked on in matters of tumorigenesis and leukemogenesis. Therefore, in this study expression levels of ATG7 and LC3 as two key genes are targeted in AML patients. Material and method: This...

Epidemiology and incidence Acute myeloid (AML) and acute lymphocytic leukemia (ALL) are rare diseases, accounting for approximately 1.3% and 0.4% of all new cancer cases in the US. While the overall incidence of leukemia has been stable since 1975 (13 new cases/ 100,000 in 1975 and 14 new cases/ 100,000 in 2012) [1], the rates for new AML and ALL cases have been rising on average by 2.2% and 0....

An 83 year-old Caucasian male presented to the emergency room with confusion and lethargy. A complete blood count revealed lymphocytosis, anemia, and thrombocytopenia. A bone marrow examination revealed chronic lymphocytic leukemia (CLL), along with a small population of abnormal immature myeloid cells. Chemotherapy for CLL was started. After one cycle, repeat bone marrow examination revealed n...

C/EBPα is a key transcription factor regulating myeloid differentiation and leukemogenesis. The Trib1-COP1 complex is an E3 ubiquitin ligase that targets C/EBPα for degradation, and its overexpression specifically induces acute myeloid leukemia (AML). Here we show that myeloid leukemia factor 1 (MLF1) stabilizes C/EBPα protein levels by inhibiting the ligase activity of the Trib1-COP1 complex. ...

Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl(+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit(+) secondar...

MLL/GAS7, resulting from t(11;17)(q23;p13), has been reported in one case of treatment-related acute myeloid leukemia (AML). We present a de novo case of t(11;17)-positive pediatric acute lymphoblastic leukemia. Fluorescent in situ hybridization and reverse transcriptase polymerase chain reaction analyses revealed an MLL/GAS7 chimera identical to the one previously described in AML. The molecul...

A cancer diagnosis is one of the most difficult medical challenges. Leukemia a type that affects bone marrow and/or blood and accounts for approximately 8% all cancers. Understanding epidemiology trends leukemia critical planning. Specialists diagnose using morphological analysis, but there possibility error in diagnosis. Since so to diagnose, intelligent methods are required. The primary goal ...

Background/aim The chromosome translocation t(8;19)(p11;q13) has been reported in only six acute myeloid leukemia (AML) patients. We here present the genetic and clinical features of seventh AML case with this aberration. Materials methods Cytogenetic molecular investigations were performed on leukemic bone marrow cells from a patient therapy-related AML. Results A was found leading to an in-fr...